CD27 and prostate cancer: Anti-CD27 antibody and RM-1 (mouse prostate cancer cell line) tumor lysate-pulsed DCs, in combination, greatly promoted the proliferation and activity of T-cells, and remarkably declined the growth of tumor in comparison to monotherapy with RM-1 tumor lysate-pulsed DCs or anti CD27 antibody (Wei et al., 2015[99]).